PD
FHTX icon

Point72 (DIFC)’s Foghorn Therapeutics FHTX Stock Holding History

Point72 (DIFC)’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-481
Closed -$2.26K – 1409
2025
Q2 		$2.26K Buy
481
+105
+28% +$439 ﹤0.01% 1418
2025
Q1 		$1.37K Sell
376
-133
-26% -$606 ﹤0.01% 1578
2024
Q4 		$2.4K Buy
+509
New +$3.71K ﹤0.01% 1422

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Point72 (DIFC)'s FHTX Position: Q3 2025 in Review

Point72 (DIFC) sold out of Foghorn Therapeutics (FHTX) in Q3 2025, closing a stake of 481 shares — an estimated $2.26K sold.

Point72 (DIFC) first reported a position in FHTX in Q4 2024 and held it in 3 quarters. The position peaked at $2.4K in Q4 2024. 88 funds tracked by Wall St. Rank hold FHTX as of Q3 2025.

  • Point72 (DIFC) reported no remaining Foghorn Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 481 Foghorn Therapeutics shares in Q3 2025, an estimated $2.26K.
  • Point72 (DIFC) first reported a position in Foghorn Therapeutics in Q4 2024 and held it in 3 quarters.
  • Point72 (DIFC)'s Foghorn Therapeutics position peaked at $2.4K in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.